-
肺癌是目前世界上最常见的癌症之一,在所有的恶性肿瘤中,肺癌的病死率高居榜首。根据肺癌肿瘤细胞的病理学类型,其主要分为小细胞肺癌、大细胞肺癌、鳞癌和腺癌,后三者统称为非小细胞肺癌(non-small cell lung cancer, NSCLC),约占所有肺癌的85%[1]。大约15%~20%的NSCLC是早期的、局灶的并且可以通过手术治疗,此型患者的预后最好。在指导原发性NSCLC的治疗方案上,TNM分期是预测预后最重要的指标,其传统上是基于手术结果和常规影像学,以解剖结构为基础,但未能体现生物学行为。对于病理特征相似的同一分期患者,即使使用同样的治疗方案,疗效及生存期也会有很大不同[2]。以往的一般影像诊断程序局限于胸部X光片、螺旋CT扫描、MRI、超声和放射性核素骨扫描,而PET/CT作为一种功能显像方法已经广泛应用于肺癌的诊断、分期和疗效评价等方面。目前已证实18F-FDG PET/CT显像中的定量及半定量参数可以评估肿瘤的代谢情况,包括病灶区域SUVmax、病灶区域平均标准化摄取值(mean standardized uptake value,SUVmean)、小区域最大摄取值(peak standardized uptake value,SUVpeak)、肿瘤代谢体积(metabolic tumor volume,MTV)和肿瘤糖酵解总量(total lesion glycolysis,TLG)等。我们就上述相关参数在可手术切除NSCLC患者预后中的应用作综述。
术前18F-FDG PET/CT显像代谢参数在非小细胞肺癌患者预后评估中的应用进展
Application progress of preoperative 18F-FDG PET/CT imaging metabolic parameters in the prognostic evaluation of patients with non-small cell lung cancer
-
摘要: 肺癌是目前世界上最常见的癌症之一,在所有的恶性肿瘤中,肺癌的病死率高居榜首,而非小细胞肺癌(NSCLC)约占所有肺癌的85%。18F-氟脱氧葡萄糖(FDG)PET/CT作为一种从分子水平反映肿瘤细胞代谢状态的功能显像方法,已成为NSCLC诊断、分期和疗效评价的重要工具。18F-FDG PET/CT可检测出常规CT遗漏的其他病变部位,在肺癌患者的手术切除预后方面起着越来越重要的作用。笔者就18F-FDG PET/CT相关代谢参数在预测可手术切除NSCLC患者预后方面的应用进展进行综述。
-
关键词:
- 氟脱氧葡萄糖F18 /
- 正电子发射断层显像术 /
- 体层摄影术,X线计算机 /
- 癌,非小细胞肺 /
- 最大标准化摄取值 /
- 预后
Abstract: Lung cancer is one of the commonest cancers in the world. Among all malignant tumors, lung cancer has the highest fatality rate, while non-small cell lung cancer (NSCLC) accounts for about 85% of all lung cancer. As a functional imaging method that reflects the metabolic status of tumor cells at the molecular level, 18F-fluorodeoxyglucose (FDG) PET/CT has become an important tool for diagnosis, staging and efficacy evaluation of NSCLC. 18F-FDG PET/CT plays an increasingly important role in the prognosis of the patients with surgically resected NSCLC, because it can detect lesions left out by conventional CT. This paper reviews the application progress of 18F-FDG PET/CT related metabolic parameters in predicting the prognosis of resectable NSCLC. -
[1] Deslypere G, Gullentops D, Wauters E, et al. Immunotherapy in non-metastatic non-small cell lung cancer: can the benefits of stage Ⅳ therapy be translated into earlier stages?[J]. Ther Adv Med Oncol, 2018, 10: 1-11. DOI: 10.1177/1758835918772810. [2] Cheng G, Huang H. Prognostic value of 18F-fluorodeoxyglucose PET/computed tomography in non-small-cell lung cancer[J]. PET Clin, 2018, 13(1): 59−72. DOI: 10.1016/j.cpet.2017.08.006. [3] Paesmans M, Berghmans T, Dusart M, et al. Primary tumor standardized uptake value measured on fluorodeoxyglucose positron emission tomography is of prognostic value for survival in non-small cell lung cancer: update of a systematic review and meta-analysis by the European Lung Cancer Working Party for the International Association for the Study of Lung Cancer Staging Project[J]. J Thorac Oncol, 2010, 5(5): 612−619. DOI: 10.1097/JTO.0b013e3181d0a4f5. [4] Liu J, Dong M, Sun X, et al. Prognostic value of 18F-FDG PET/CT in surgical non-small cell lung cancer: a meta-analysis[J/OL]. PLoS One, 2016, 11(1): e0146195[2019-08-27]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4699812. DOI: 10.1371/journal.pone.0146195. [5] Paesmans M, Garcia C, Wong CYO, et al. Primary tumour standardised uptake value is prognostic in nonsmall cell lung cancer: a multivariate pooled analysis of individual data[J]. Eur Respir J, 2015, 46(6): 1751−1761. DOI: 10.1183/13993003.00099-2015. [6] Konings R, van Gool MH, Bard MPL, et al. Prognostic value of pre-operative glucose-corrected maximum standardized uptake value in patients with non-small cell lung cancer after complete surgical resection and 5-year follow-up[J]. Ann Nucl Med, 2016, 30(5): 362−368. DOI: 10.1007/s12149-016-1070-2. [7] Murakami S, Saito H, Sakuma Y, et al. Prognostic value of preoperative FDG-PET in stage IA lung adenocarcinoma[J]. Eur J Radiol, 2012, 81(8): 1891−1895. DOI: 10.1016/j.ejrad.2011.04.007. [8] Ohtaki Y, Shimizu K, Kaira K, et al. Risk factors associated with recurrence of surgically resected node-positive non-small cell lung cancer[J]. Surg Today, 2016, 46(10): 1196−1208. DOI: 10.1007/s00595-015-1301-5. [9] de Jong WK, van der Heijden HFM, Pruim J, et al. Prognostic value of different metabolic measurements with fluorine-18 fluorodeoxyglucose positron emission tomography in resectable non-small cell lung cancer: a two-center study[J]. J Thorac Oncol, 2007, 2(11): 1007−1012. DOI: 10.1097/JTO.0b013e31815608f5. [10] Liu S, Yin H, Ji HY, et al. Overexpression of TRIM44 is an independent marker for predicting poor prognosis in epithelial ovarian cancer[J]. Exp Ther Med, 2018, 16(4): 3034−3040. DOI: 10.3892/etm.2018.6541. [11] Agarwal M, Brahmanday G, Bajaj SK, et al. Revisiting the prognostic value of preoperative 18F-fluoro-2-deoxyglucose 18F-FDG positron emission tomography (PET) in early-stage (Ⅰ & Ⅱ) non-small cell lung cancers (NSCLC)[J]. Eur J Nucl Med Mol Imaging, 2010, 37(4): 691−698. DOI: 10.1007/s00259-009-1291-x. [12] Horne ZD, Clump DA, Vargo JA, et al. Pretreatment SUVmax predicts progression-free survival in early-stage non-small cell lung cancer treated with stereotactic body radiation therapy[J]. Radiat Oncol, 2014, 9: 41[2019-08-27]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3922961. DOI: 10.1186/1748-717X-9-41. [13] Lee VHF, Chan WWL, Lee EYP, et al. Prognostic significance of standardized uptake value of lymph nodes on survival for stage Ⅲ non-small cell lung cancer treated with definitive concurrent chemoradiotherapy[J]. Am J Clin Oncol, 2016, 39(4): 355−362. DOI: 10.1097/COC.0000000000000070. [14] Carvalho S, Leijenaar RTH, Troost EGC, et al. 18F-fluorodeoxyglucose positron-emission tomography (FDG-PET)-Radiomics of metastatic lymph nodes and primary tumor in non-small cell lung cancer (NSCLC)-a prospective externally validated study[J/OL]. PLoS One, 2018, 13(3): e192859[2019-08-27]. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5832210. DOI: 10.1371/journal.pone.0192859. [15] Sasaki R, Komaki R, Macapinlac H, et al. [18F]fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non–small-cell lung cancer[J]. J Clin Oncol, 2005, 23(6): 1136−1143. DOI: 10.1200/JCO.2005.06.129. [16] 王涛, 王振光. 18F-FDG PET/CT代谢参数在非小细胞肺癌预后评估中的应用及进展[J]. 中国肺癌杂志, 2019, 22(3): 167−172. DOI: 10.3779/j.issn.1009-3419.2019.03.09.
Wang T, Wang ZG. Application of metabolic parameters measured by 18F-FDG PET/CT in the evaluation of the prognosis of non-small cell lung cancer[J]. Chin J Lung Cancer, 2019, 22(3): 167−172. DOI: 10.3779/j.issn.1009-3419.2019.03.09.[17] Bazan JG, Duan FH, Snyder BS, et al. Metabolic tumor volume predicts overall survival and local control in patients with stage Ⅲ non-small cell lung cancer treated in ACRIN 6668/RTOG 0235[J]. Eur J Nucl Med Mol Imaging, 2017, 44(1): 17−24. DOI: 10.1007/s00259-016-3520-4. [18] Zhang H, Wroblewski K, Appelbaum D, et al. Independent prognostic value of whole-body metabolic tumor burden from FDG-PET in non-small cell lung cancer[J]. Int J Comput Assist Radiol Surg, 2013, 8(2): 181−191. DOI: 10.1007/s11548-012-0749-7. [19] Aktas GE, Karamustafaoğlu YA, Balta C, et al. Prognostic significance of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography-derived metabolic parameters in surgically resected clinical-no nonsmall cell lung cancer[J]. Nucl Med Commun, 2018, 39(11): 995−1004. DOI: 10.1097/MNM.0000000000000903. [20] 郑庆中, 苏洁敏, 邓菁, 等. 18F-FDG PET/CT代谢参数对116例非小细胞肺癌患者预后评估价值[J]. 中华肿瘤防治杂志, 2020, 27(16): 1309−1314. DOI: 10.16073/j.cnki.cjcpt.2020.16.06.
Zheng QZ, Su JM, Deng J, et al. Prognostic value of 18F-FDG PET/CT metabolic parameters in patients with non-small cell lung cancer[J]. Chin J Cancer Prev Treat, 2020, 27(16): 1309−1314. DOI: 10.16073/j.cnki.cjcpt.2020.16.06.[21] Burger IA, Vargas HA, Apte A, et al. PET quantification with a histogram derived total activity metric: superior quantitative consistency compared to total lesion glycolysis with absolute or relative SUV thresholds in phantoms and lung cancer patients[J]. Nucl Med Biol, 2014, 41(5): 410−418. DOI: 10.1016/j.nucmedbio.2014.02.006. [22] Im HJ, Pak K, Cheon GJ, et al. Prognostic value of volumetric parameters of 18F-FDG PET in non-small-cell lung cancer: a meta-analysis[J]. Eur J Nucl Med Mol Imaging, 2015, 42(2): 241−251. DOI: 10.1007/s00259-014-2903-7. [23] 陈挺, 张宏, 田梅, 等. 18F-FDG PET/CT代谢半定量参数在非小细胞肺癌预后评估中的价值[J]. 国际放射医学核医学杂志, 2018, 42(3): 269−273. DOI: 10.3760/cma.j.issn.1673-4114.2018.03.014.
Chen T, Zhang H, Tian M, et al. Prognostic evaluation of patients with non-small cell lung cancer by using semi-quantitative metabolic parameters of 18F-FDG PET/CT[J]. Int J Radiat Med Nucl Med, 2018, 42(3): 269−273. DOI: 10.3760/cma.j.issn.1673-4114.2018.03.014.[24] Kim K, Kim SJ, Kim I J, et al. Prognostic value of volumetric parameters measured by F-18 FDG PET/CT in surgically resected non-small-cell lung cancer[J]. Nucl Med Commun, 2012, 33(6): 613−620. DOI: 10.1097/MNM.0b013e328351d4f5.
计量
- 文章访问数: 3025
- HTML全文浏览量: 2121
- PDF下载量: 16